Search

448 Result(s)
Sort by

Agreement-to-acquire-Labor-Dr.-Merk

Agreement-to-acquire-Labor-Dr.-Merk

Boehringer Ingelheim to acquire Labor Dr. Merk & Kollegen to strengthen its next generation cancer immunology program
Zactran®

Zactran®

Depending on species indication (and country of registration), the product is for the treatment and metaphylaxis control of respiratory disease in cattle caused by key bacteria (Mannheimia, Pasteurella, Histophilus and Mycoplasma) and footrot disease
Yanina Donatini

Yanina Donatini

Yanina Donatini, Head of ITM&S Content Production at Boehringer Ingelheim speaks about her 20 years in the company as innovative and diverse.
About Chronic Kidney Disease

About Chronic Kidney Disease

CKD is very common and often goes undetected due to its silent nature. Risk factors include high blood pressure and type 2 diabetes.
Jan-Erik Schafer

Jan-Erik Schafer

Jan Erik, Senior Team Leader in the upstream pharmaceutical production talks about his motivating and fun career at Boehringer Ingelheim.
Dominik Huber

Dominik Huber

Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Ingelheim

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.
Biberach

Biberach

The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Our-position

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial